Guidelines aim to clarify treatment of pre-diabetes. The. American. College. of Endocrinology last week issued its first guidelines on managing patients with pre-diabetes, suggesting aggressive lifestyle control as the ... Will the new recommendations
QD: News Every Day--Residents aren't learning how to treat diabetes properly. ... Internal medicine residency programs aren't doing enough to teach quality treatment for diabetes, concluded a study, which doesn't bode well for doctors who will eventually
Research indicates that risk for heart failure in patients with diabetes increases with HbA1c level, Dr. ... Mitchell. “Certainly the treatment of diabetes is relevant to all specialties,” she said.
King said. SGLT2 inhibitors, approved to treat diabetes, have shown positive effects on renal and cardiovascular outcomes and thus caused excitement among the relevant subspecialists.
Surgery for Diabetes May Be Better Than Standard Treatment (New York Times article). ... Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes (New England Journal of Medicine article).
This regulatory update covers dapaglifozin (Farxiga) a sodium-glucose co-transporter 2 inhibitor, to treat diabetes, and umeclidinium and vilanterol inhalation (Anoro Ellipta) for maintenance of chronic obstructive pulmonary disease. ... It should not be
31, 2015. Canaglifozin (Invokana) tablets, to improve glycemic control in adults with type 2 diabetes, along with diet and exercise. ... It should not be used in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment or end-stage
The prospective InterAct case-cohort study conducted in 26 centers in eight European countries, is investigating how genetics and lifestyle interact to affect diabetes risk. ... Waist circumference is just as important as other risk factors for diabetes
This update covers approval of a sodium-glucose co-transporter 2 inhibitor for diabetes, a once-daily long-acting beta-adrenergic agonist (LABA) for chronic obstructive pulmonary disease (COPD), and a ... Empagliflozin (Jardiance) to treat type 2
The FDA continues to investigate and has not determined whether the diabetes drug increases the risk of leg and foot amputations.